Uscript Author ManuscriptReference1. Doran MF, Crowson CS, Pond GR, et al.Uscript Author ManuscriptReference1. Doran MF,

Uscript Author ManuscriptReference1. Doran MF, Crowson CS, Pond GR, et al.
Uscript Author ManuscriptReference1. Doran MF, Crowson CS, Pond GR, et al. Predictors of infection in rheumatoid arthritis. Arthritis Rheumatism. 2002; 46(9):2294sirtuininhibitor00. [PubMed: 12355476] two. Capell HA. Disease Artemin Protein site modifying antirheumatic drugs: longterm security challenges. J Rheumatol Suppl. 2001; 62:10sirtuininhibitor. Epub 2001/06/21. [PubMed: 11409152] 3. Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-alpha antagonists along with the danger of hospitalization for infection in sufferers with autoimmune diseases. JAMA : the journal with the American Medical Association. 2011; 306(21):2331sirtuininhibitor. Epub 2011/11/08. 4. Curtis JR, Patkar N, Xie A, et al. Risk of critical REG-3 alpha/REG3A Protein medchemexpress bacterial infections among rheumatoid arthritis sufferers exposed to tumor necrosis aspect alpha antagonists. Arthritis Rheum. 2007; 56(four):1125sirtuininhibitor3. [PubMed: 17393394] five. Curtis JR, Xie F, Chen L, et al. The comparative threat of really serious infections among rheumatoid arthritis individuals beginning or switching biological agents. Ann Rheum Dis. 2011; 70(eight):1401sirtuininhibitor. Epub 2011/05/19. [PubMed: 21586439] six. Curtis JR, Xi J, Patkar N, et al. Drug-specific and time-dependent risks of bacterial infection among sufferers with rheumatoid arthritis who have been exposed to tumor necrosis aspect alpha antagonists. Arthritis Rheum. 2007; 56(12):4226sirtuininhibitor. [PubMed: 18050253] 7. Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific danger of tuberculosis in sufferers with rheumatoid arthritis treated with anti-TNF therapy: Results in the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2009 Epub 2009/10/27. eight. Dixon WG, Symmons DP, Lunt M, et al. Significant infection following anti-tumor necrosis aspect alpha therapy in individuals with rheumatoid arthritis: lessons from interpreting information from observational studies. Arthritis Rheum. 2007; 56(9):2896sirtuininhibitor04. Epub 2007/09/01. [PubMed: 17763441] 9. Johnston SS, Turpcu A, Shi N, et al. Danger of infections in rheumatoid arthritis individuals switching from anti-TNF agents to rituximab, abatacept, or a different anti-TNF agent, a retrospective administrative claims analysis. Seminars in arthritis and rheumatism. 2013 Epub 2013/03/05. 10. Schneeweiss S, Setoguchi S, Weinblatt ME, et al. Anti-tumor necrosis element alpha therapy as well as the danger of severe bacterial infections in elderly sufferers with rheumatoid arthritis. Arthritis Rheum. 2007; 56(6):1754sirtuininhibitor4. [PubMed: 17530704] 11. Listing J, Strangfeld A, Kary S, et al. Infections in sufferers with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005; 52(11):3403sirtuininhibitor2. [PubMed: 16255017] 12. Dewedar AM, Shalaby MA, Al-Homaid S, et al. Lack of adverse impact of anti-tumor necrosis factor-alpha biologics in therapy of rheumatoid arthritis: 5 years follow-up. International journal of rheumatic ailments. 2012; 15(three):330sirtuininhibitor. Epub 2012/06/20. [PubMed: 22709496] 13. Keyser FD. Option of Biologic Therapy for Individuals with Rheumatoid Arthritis: The Infection Point of view. Present rheumatology evaluations. 2011; 7(1):77sirtuininhibitor7. Epub 2011/11/15. [PubMed: 22081766] 14. Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Seminars in arthritis and rheumatism. 2010; 39(5):327sirtuininhibitor6. Epub 2009/01/02. [PubMed: 19117595] 15. Hyrich KL, Lunt M, Watson KD, et al. Outcomes immediately after switching from one particular anti-tumor necrosis factor alpha agent to a.